BetterLife Pharma Inc.
No enriched coverage for $BETRF in the last 7 days.
No SEC Form 4 filings for $BETRF in the last 30 days.
See all $BETRF insider activity →BetterLife Pharma Inc. (CSE: BETR) filed a preliminary prospectus for a public offering of common shares and pre-funded warrants. The biotech firm plans to use proceeds for clinical trials and working capital, with the offering expected to close by September 15, 2026, subject to regulatory approvals.
BetterLife Pharma Inc. (CSE: BETR) filed a preliminary prospectus for a public offering of common shares and pre-funded warrants. The biotech firm plans to use proceeds for clinical trials and working capital, with the offering expected to close by September 15, 2026, subject to regulatory approvals.
alphai scores every news story that mentions BETRF with an AI model for sentiment and relevance, and aggregates insider trades from BetterLife Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BetterLife Pharma Inc. (CSE: BETR) filed a preliminary prospectus for a public offering of common shares and pre-funded warrants. The biotech firm plans to use proceeds for clinical trials and working capital, with the offering expected to close by September 15, 2026, subject to regulatory approvals.
2 min read